|
US2373192A
(en)
|
1943-03-13 |
1945-04-10 |
Walter M Lauer |
Antioxidants
|
|
US4567253A
(en)
|
1984-02-03 |
1986-01-28 |
Tony Durst |
2-Substituted derivatives of podophyllotoxin and etoposide
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
|
US8178304B2
(en)
|
2000-10-06 |
2012-05-15 |
Smith Terry J |
Diagnostic methods relating to Graves' disease and other autoimmune disorders
|
|
ME00502B
(me)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antitjela za insulinu sličan receptor faktora i rasta
|
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
|
TWI238824B
(en)
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
WO2005058967A2
(en)
|
2003-12-16 |
2005-06-30 |
Pierre Fabre Medicament |
Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
|
|
EP2168968B1
(en)
|
2004-04-02 |
2017-08-23 |
OSI Pharmaceuticals, LLC |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
|
FR2873699B1
(fr)
*
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
ES2426482T3
(es)
|
2005-01-27 |
2013-10-23 |
Kyowa Hakko Kirin Co., Ltd. |
Inhibidor de IGF-1R
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
ES2545907T3
(es)
|
2005-12-29 |
2015-09-16 |
Abbvie Inc. |
Inhibidores de proteína quinasa
|
|
AU2007245164A1
(en)
|
2006-03-28 |
2007-11-08 |
Biogen Idec Ma Inc. |
Anti-IGF-IR antibodies and uses thereof
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
HRP20140688T1
(hr)
|
2006-07-07 |
2014-10-24 |
Bristol-Myers Squibb Company |
Inhibitori piroltriazin kinaze
|
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
|
JP2010506941A
(ja)
|
2006-10-17 |
2010-03-04 |
リセラ，インク． |
甲状腺眼症の治療のための方法、組成物及び製剤
|
|
CN101932580B
(zh)
|
2007-06-01 |
2013-05-22 |
葛兰素史密丝克莱恩有限责任公司 |
咪唑并吡啶激酶抑制剂
|
|
ES2424977T3
(es)
|
2007-08-08 |
2013-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
|
|
CA2697612A1
(en)
*
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Anti-igf-1r antibodies and uses thereof
|
|
TW201211036A
(en)
|
2010-06-17 |
2012-03-16 |
Kyowa Hakko Kirin Co Ltd |
Useful salts of indazole derivative
|
|
MX2013000617A
(es)
|
2010-07-16 |
2013-06-13 |
Piramal Entpr Ltd |
Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
US8546443B2
(en)
|
2010-12-21 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Benzylic oxindole pyrimidines
|
|
US8476409B2
(en)
|
2011-04-19 |
2013-07-02 |
Merrimack Pharmaceuticals, Inc. |
Bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
AU2012245971A1
(en)
|
2011-04-21 |
2013-10-17 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
WO2013110585A1
(en)
|
2012-01-23 |
2013-08-01 |
Boehringer Ingelheim International Gmbh |
5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
WO2016064716A1
(en)
|
2014-10-20 |
2016-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapy of tshr antagonist and igfr inhibitor
|
|
JP6664414B2
(ja)
|
2015-05-13 |
2020-03-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＩＧＦ−１Ｒ／ＩＲ阻害薬としての新規５，８−ジメチル−９−フェニル−５，８−ジヒドロ−６Ｈ−ピラゾロ［３，４−ｈ］キナゾリン−２−イル）−（１Ｈ−ピラゾール−３−イル）−アミン及び誘導体
|
|
US20210284741A1
(en)
*
|
2018-01-24 |
2021-09-16 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
US11208489B2
(en)
*
|
2018-01-24 |
2021-12-28 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of thyroid eye disease
|
|
US10457740B1
(en)
*
|
2018-01-29 |
2019-10-29 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions for treating cancer using P2RX2 inhibitors
|
|
WO2019173352A1
(en)
|
2018-03-05 |
2019-09-12 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
AU2020337958A1
(en)
|
2019-08-28 |
2022-03-17 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of thyroid eye disease
|